(+)-Boc-MCBI | 173655-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (+)-Boc-MCBI
• 英文别名: tert-butyl (1R,13S)-4-methoxy-8-oxo-11-azatetracyclo[8.4.0.01,13.02,7]tetradeca-2(7),3,5,9-tetraene-11-carboxylate
• CAS: 173655-21-5
• 化学式: C₁₉H₂₁NO₄
• 分子量: 327.38
• InChiKey: AUDJQODGILRJBC-NSPYISDASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+)-Boc-MCBI 以 甲醇 、 水 为溶剂， 生成
  参考文献：
  名称：

  A Hammett correlation for CC-1065 and duocarmycin analogs: Magnitude of substituent electronic effects on functional reactivity

  摘要：

  A quantitative Hammett study of the magnitude of the electronic effects of a C7 substituent on the functional reactivity of N-BOC-CBI (5, R = H), its impact on biological properties, details of the mechanism of the acid-catalyzed nucleophilic addition to the activated cyclopropane, and its implications on the origin of the DNA alkylation selectivity of this class of agents is detailed.

  DOI：

  10.1016/0960-894x(96)00093-5
• 作为产物：
  描述：

  7-甲氧基-4-苯基甲氧基萘-2-羧酸乙酯 在 palladium on activated charcoal 四氯化碳 、 lithium hydroxide 、 N-碘代丁二酰亚胺 、 二苯基磷酸 、 水 、 三正丁基氢锡 、 甲酸铵 、 sodium hydride 、 对甲苯磺酸 、 三乙胺 、 三苯基膦 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 丙酮 、 paraffin 、 苯 为溶剂， 反应 58.75h， 生成 (+)-Boc-MCBI
  参考文献：
  名称：

  CC-1065和掺入7-甲氧基-1,2,9,9a-四氢环丙烷[c]苯并[e]吲哚-4-酮（MCBI）烷基化亚基的Duocarcins的取代CBI类似物的合成和性质对功能反应性的影响。

  摘要：

  在以下文献中描述了7-甲氧基-1,2,9,9a-四氢环丙烷[c]苯并[e]吲哚-4-酮（MCBI）的合成，MCBI是带有对C4羰基的C7甲氧基的取代的CBI衍生物。努力确定对试剂的化学和功能反应性的潜在电子效应的大小。通过修饰的Stobbe缩合/ Friedel-Crafts酰化反应制备MCBI烷基化亚基的核心结构，以生成适当官能化的萘前体（15和20），然后进行5-exo-trig芳基自由基-烯烃环化（24-> 25、32-> 33）完成1，2-二氢-3H-苯并[e]吲哚骨架的合成，最后28的Ar-3'烷基化，以引入活化的环丙烷。详细介绍了实现关键的5-exo-trig自由基环化的两种方法，前者以24结束，以提供25，其中在环化之前引入了所需的产品功能化，而后者则用了环化产物的Tempo捕集器官能化的未反应的烯烃底物32提供33％。后一种简洁的方法以极好的总转化率（27-30％）以12-

  DOI：

  10.1021/jo952033g

文献信息

• SELENOPHENE-FUSED AROMATIC COMPOUND AND MANUFACTURING METHOD THEREOF
  申请人：Samsung Life Public Welfare Foundation

  公开号：US20140213790A1

  公开（公告）日：2014-07-31

  The present disclosure relates to a method for more easily and economically producing a selenophene-fused aromatic compound derivative containing various substituents and the selenophene-fused aromatic compound produced according to the method, and the selenophene-fused aromatic compound can be used for various purposes such as an intermediate of an anti-bacterial or anticancer substance, an indicator of which color is changed depending on a solvent, or a fluorescent substance.

  本公开涉及一种更容易和经济地生产含有各种取代基的硒杂吩并芳香化合物衍生物的方法，以及根据该方法生产的硒杂吩并芳香化合物，该硒杂吩并芳香化合物可用于各种用途，如抗菌或抗癌物质的中间体，根据溶剂改变颜色的指示剂，或荧光物质。
• Synthesis and biological evaluation of potent benzoselenophene and heteroaromatic analogues of (<i>S</i>)-1-(chloromethyl)-8-methoxy-2,3-dihydro-1<i>H</i>-benzo[<i>e</i>]indol-5-ol (<i>seco</i>-MCBI)
  作者：Amol B. Mhetre、Eppakayala Sreedhar、Rashmi Dubey、Ganesh A. Sable、Hangeun Lee、Heekyoung Yang、Kyoungmin Lee、Do-Hyun Nam、Dongyeol Lim

  DOI：10.1039/c9ra04749b

  日期：——

  A diverse series of compounds (18a–x) were synthesized from (S)-1-(chloromethyl)-8-methoxy-2,3-dihydro-1H-benzo[e]indol-5-ol (seco-MCBI) and benzoselenophene or heteroaromatic acids. These new compounds were evaluated for their cytotoxicity against the human gastric NCI-N87 and human ovarian SK-OV3 cancer cell lines. The incorporation of a methoxy substituent at the C-7 position of the seco-CBI unit

  由( S )-1-(氯甲基)-8-甲氧基-2,3-二氢-1H-苯并[ e ]吲哚-5-醇( seco -MCBI)合成了一系列不同的化合物( 18a– x)和苯并硒吩或杂芳酸。评估了这些新化合物对人胃 NCI-N87 和人卵巢 SK-OV3 癌细胞系的细胞毒性。在seco -CBI 单元的 C-7 位置掺入甲氧基取代基通过其额外的范德华相互作用增强了细胞毒性，并且比相应的基于seco -CBI 的类似物具有更高的效力。同样，seco -MCBI-苯并硒吩缀合物 ( 18h–x ) 对生物活性表现出取代效应，并且N -丁酰胺基和N -甲硫基丙酰胺基类似物非常有效，其活性比seco -MCBI高 77 倍和 24 倍-TMI 分别用于 SK-OV3 和 NCI-N87 细胞系。
• Synthesis and Evaluation of CC-1065 and Duocarmycin Analogues Incorporating the Iso-CI and Iso-CBI Alkylation Subunits:  Impact of Relocation of the C-4 Carbonyl
  作者：Dale L. Boger、Robert M. Garbaccio、Qing Jin

  DOI：10.1021/jo971686p

  日期：1997.12.1

  The synthesis of 2-(tert-Butyloxycarbonyl)-1, 2, 9, 9a-tetrahydrocyclopropa[c]benzo[f]indol-8-one (31, N-BOC-iso-CBI) and 1-(tert-Butyloxycarbonyl)-4-hydroxy-3-[[(methanesulfonyl)oxy]methyl]-2, 3-dihydroindole (19, seco-N-BOC-iso-CI) containing an isomeric structural modification in the CC-1065 and duocarmycin alkylation subunits and their incorporation into analogues of the natural products are detailed. The approach was based on a directed ortho metalation of an appropriately functionalized benzene (13) or naphthalene (24) precursor to regiospecifically install iodine at the C-2 position. Conversion of these respective intermediates to the dihydroindole skeleton utilized an established 5-exo-trig aryl radical cyclization onto an unactivated alkene with subsequent TEMPO trap or the more recent 5-exo-trig aryl radical cyclization onto a vinyl chloride for direct synthesis of the immediate precursors. Closure of the activated cyclopropane to complete the iso-CBI nucleus was accomplished by a selective ortho spirocyclization. The evaluation of the iso-CBI-based agents revealed a significant stability comparable to that of CC-1065 and duocarmycin A, but that it is more reactive than duocarmycin SA (6 - 7x) or the direct comparison CBI-based agents (5x) for which X-ray structure comparisons served to establish the basis for their inherent reaction regioselectivity and reactivity. Resolution and synthesis of a full set of natural product analogues and subsequent evaluation of their DNA alkylation properties revealed that the iso-CBI analogues, even with the relocation of the C-4 carbonyl and the most substantial structural modifications to the alkylation subunit to date, reacted at comparable rates and retain the identical and characteristic sequence selectivity of CC-1065 and the duocarmycins. This observation is inconsistent with the proposal that a sequence-dependent C-4 carbonyl protonation by strategically located DNA backbone phosphates controls the DNA alkylation selectivity but is consistent with the proposal that it is determined by the AT-rich noncovalent binding selectivity of the agents and the steric accessibility of the N3 alkylation site. Confirmation that the DNA alkylation reaction is derived from adenine N3 addition to the least substituted carbon of the activated cyclopropane, and its quantitation (95%) was established by isolation and characterization of the depurination adenine N3 adduct. Consistent with past studies and despite the deep-seated structural change in the alkylation subunit, the agents were found to exhibit potent cytotoxic activity that correlates with their inherent reactivity.
• ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF
  申请人：IntoCell, Inc.

  公开号：US20230190939A1

  公开（公告）日：2023-06-22

  The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said drugs or toxins, cleavable linkers, and targeting moieties. The present disclosure also relates to methods of treating cancers, auto-immune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.
• Synthesis and Properties of Substituted CBI Analogs of CC-1065 and the Duocarmycins Incorporating the 7-Methoxy-1,2,9,9a-tetrahydrocyclopropa[<i>c</i>]benz[<i>e</i>]indol-4-one (MCBI) Alkylation Subunit:  Magnitude of Electronic Effects on the Functional Reactivity
  作者：Dale L. Boger、Jeffrey A. McKie、Hui Cai、Barbara Cacciari、P. G. Baraldi

  DOI：10.1021/jo952033g

  日期：1996.1.1

  radical-alkene cyclization (24 --> 25, 32 --> 33) for completion of the synthesis of the 1,2-dihydro-3H-benz[e]indole skeleton and final Ar-3' alkylation of 28 for introduction of the activated cyclopropane. Two approaches to the implementation of the key 5-exo-trig free radical cyclization are detailed with the former proceeding with closure of 24 to provide 25 in which the required product functionalization was

  在以下文献中描述了7-甲氧基-1,2,9,9a-四氢环丙烷[c]苯并[e]吲哚-4-酮（MCBI）的合成，MCBI是带有对C4羰基的C7甲氧基的取代的CBI衍生物。努力确定对试剂的化学和功能反应性的潜在电子效应的大小。通过修饰的Stobbe缩合/ Friedel-Crafts酰化反应制备MCBI烷基化亚基的核心结构，以生成适当官能化的萘前体（15和20），然后进行5-exo-trig芳基自由基-烯烃环化（24-> 25、32-> 33）完成1，2-二氢-3H-苯并[e]吲哚骨架的合成，最后28的Ar-3'烷基化，以引入活化的环丙烷。详细介绍了实现关键的5-exo-trig自由基环化的两种方法，前者以24结束，以提供25，其中在环化之前引入了所需的产品功能化，而后者则用了环化产物的Tempo捕集器官能化的未反应的烯烃底物32提供33％。后一种简洁的方法以极好的总转化率（27-30％）以12-